AtriCure (NASDAQ:ATRC – Get Rating) had its price target raised by Stifel Nicolaus from $48.00 to $50.00 in a report released on Wednesday, The Fly reports. A number of other brokerages have also issued reports on ATRC. BTIG Research cut their price target on shares of AtriCure from $65.00 to $55.00 and set a buy […]
AtriCure (NASDAQ:ATRC – Get Rating) had its price target hoisted by equities research analysts at Stifel Nicolaus from $48.00 to $50.00 in a report released on Wednesday, The Fly reports. Stifel Nicolaus’ price target points to a potential upside of 6.09% from the company’s previous close. ATRC has been the subject of a number of […]
AtriCure (NASDAQ:ATRC – Get Rating) updated its FY 2023 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of -$1.15–$1.10 for the period, compared to the consensus estimate of -$1.10. The company issued revenue guidance of $385.00 million-$392.00 million, compared to the consensus revenue estimate of $382.67 million. Wall Street Analyst Weigh […]
Thornburg Investment Management Inc. lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 4.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 121,007 shares of the medical device company’s stock after selling 5,919 shares during the quarter. Thornburg Investment Management Inc.’s holdings in AtriCure were worth $5,370,000 as of […]
AtriCure (NASDAQ:ATRC – Get Rating) released its quarterly earnings data on Tuesday. The medical device company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.11, Briefing.com reports. The company had revenue of $93.49 million for the quarter, compared to the consensus estimate of $87.53 million. AtriCure had a […]